Sarcopenia: From definition to treatment

Dionyssiotis, Yannis; Kapsokoulou, Athina; Samlidi, Eleni; Angoules, Antonios G; Papathanasiou, Jannis; Chronopoulos, Efstathios; Kostoglou-Athanassiou, Ifigenia; Trovas, George

doi:10.14310/horm.2002.1764

Cited by 12 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, no general consensus exists on the definition of muscle mass depletion, partly due to diverse measurement tools in assessing skeletal muscle mass and conceptual confusion between the disease or condition related to low muscle mass and frailty 5 . Imaging technologies, such as computed tomography and magnetic resonance imaging, are precise and valid but cannot be used in general population because of high cost and lack of feasibility 6 .…”

Section: Introductionmentioning

confidence: 99%

Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder

Kim

Park

et al. 2019

Sci Rep

View full text Add to dashboard Cite

This study aimed to evaluate the most valid index among various indices of low muscle mass in assessing cardiometabolic risks in a Korean population. Appendicular lean mass index (ALMI, kg/m2), fat mass index (FMI, kg/m2), FMI-adjusted ALMI (ALMfmi), ratio of ALM to weight index (ALMwt), ratio of ALM to body mass index (ALMbmi) and ratio of ALM to truncal fat index (ALMtrunkfat) were measured by dual energy X-ray absorptiometry in 17,870 participants from 2008 to 2011. We adopted all the aforementioned indices of low muscle mass expressed as sex- and age-specific standard deviation scores (Z-scores). Low muscle mass for age was defined as Z-score <−1. The prevalence of low muscle mass was approximately 16% across all indices. Low muscle mass defined by ALMI had low muscle mass and low fat mass, and ALMfmi had low muscle mass at the same FMI. However, low muscle mass defined by ALMwt, ALMbmi and ALMtrunkfat had similar muscle mass with high FMI. The receiver operating characteristic curve in metabolic syndrome showed that the ALMtrunkfat was 0.74 in male and 0.69 in female, indicating that ALMtrunkfat was the best discrimination index for metabolic syndrome. This study showed that ALMtrunkfat could be a useful indicator for screening cardiometabolic risk factors, particularly in normal or overweight Asian population.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder

Kim

Park

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…22 Sendo assim, a resistência do músculo esquelético à ação da insulina parece ser a ligação entre o diabetes tipo 2 e o risco para desenvolvimento da sarcopenia. 23 Esses dados corroboram os resultados encontrados em estudo desenvolvido com 35 pacientes, adultos e idosos, no qual pacientes diabéticos exibiram maior perda de massa muscular, resistência e capacidade funcional no curso da doença em comparação com não diabéticos, independentemente da idade. 24 Os resultados da presente investigação ampliam a discussão sobre o risco de sarcopenia em indivíduos adultos que apresentam IMC acima da normalidade, associada a uma circunferência da cintura elevada.…”

Section: Resultsunclassified

Avaliação do risco de sarcopenia em pacientes diabéticos tipo 2

Costa Lima,

De Lemos,

Lima da Silva Pastich

et al. 2024

DEMETRA

View full text Add to dashboard Cite

Introdução: Diabéticos podem apresentar perda de força e massa muscular de forma acentuada. Assim, as triagens SARC-F e SARC-CALF são úteis na investigação do risco de sarcopenia. Objetivo: Associar o risco de sarcopenia em pacientes diabéticos com as variáveis sociodemográficas, econômicas, clínicas, antropométricas e de estilo de vida. Método: Estudo do tipo série de casos realizado com adultos diabéticos tipo 2, de ambos os sexos, com idade entre 20 e 59 anos. A avaliação do risco de sarcopenia se deu pela aplicação dos questionários SARC-F e SARC-CALF. Para caracterização da amostra e associação com o risco de sarcopenia, foram coletados dados sociodemográficos e econômicos, medidas antropométricas, condições clínicas e estilo de vida. Resultados: A amostra foi composta por 69 pacientes, com média de idade de 53±7,5 anos e maior proporção de mulheres (63,8%; IC95%: 50,7-75,4). A frequência do risco positivo para sarcopenia segundo o SARC-F e o SARC-CALF foi de 43,48% e 46,38%, respectivamente. O SARC-F não mostrou associação significativa com as variáveis estudadas; já o SARC-CALF associou-se com índice de massa corporal (p <0,001), circunferência da cintura (p <0,001) e hábito de fumar (p = 0,027). Conclusão: O risco de sarcopenia foi observado em aproximadamente metade dos pacientes avaliados. O instrumento SARC-CALF apresentou associação com as variáveis antropométricas e o hábito de fumar, podendo ser considerado satisfatório para avaliar o risco de sarcopenia e intervir de forma precoce e efetiva.

show abstract

“…5 Another test is the Short Physical Performance Battery (SPPB), which is one of the most validated techniques to measure physical performance. 6 It consists of a short battery of tests designed to evaluate the functionality of the lower limbs. This battery is composed of three different sections.…”

Section: Diagnosismentioning

confidence: 99%

Sarcopenia in the Elderly

Dionyssiotis

2019

European Endocrinology

View full text Add to dashboard Cite

Sarcopenia: From definition to treatment

Cited by 12 publications

References 31 publications

Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder

Comparisons of different indices of low muscle mass in relationship with cardiometabolic disorder

Avaliação do risco de sarcopenia em pacientes diabéticos tipo 2

Sarcopenia in the Elderly

Contact Info

Product

Resources

About